

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10595386
Filing Date	2004-10-11
First Named Inventor	Roger Butlin
Art Unit	1751
Examiner Name	Not yet assigned
Attorney Docket Number	101243-1P US

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6110949	A	2000-08-29	Vilhauer, E.B et al.	
	2	6107317	A	2000-08-22	Vilhauer, E.B et al	
	3	6548481	B1	2003-04-15	Demuth, H et al	
	4	7229969	B2	2007-06-12	Ansorge, S et al	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20050014699	A1	2005-01-20	Ansorge, S et al	
	2	20060211602	A1	2006-09-21	Ansorge, S et al	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10595386
Filing Date	2004-10-11
First Named Inventor	Roger Butlin
Art Unit	1751
Examiner Name	Not yet assigned
Attorney Docket Number	101243-1P US

3	20040147434	A1	2004-07-29	Ansorge, S et al	
---	-------------	----	------------	------------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	03/031410	WO	A1	2003-04-17	Neurocrine Biosciences, Inc.		<input type="checkbox"/>
	2	03/000181	WO	A2	2003-01-03	Merck & Co, Inc.		<input type="checkbox"/>
	3	05/123685	WO	A1	2005-12-29	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
	4	04/007468	WO	A1	2004-01-22	Merck & Co, Inc.		<input type="checkbox"/>
	5	98/19998	WO	A2	1998-05-14	Novartis AG		<input type="checkbox"/>
	6	00/34241	WO	A1	2000-06-15	Novartis AG Novartis-Erfindungen		<input type="checkbox"/>
	7	01/96295	WO	A2	2001-12-20	Novartis AG Novartis-Erfindungen		<input type="checkbox"/>
	8	01/40180	WO	A2	2001-06-07	Ferring BV		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595386
Filing Date		2004-10-11
First Named Inventor	Roger Butlin	
Art Unit	1751	
Examiner Name	Not yet assigned	
Attorney Docket Number	101243-1P US	

9	01/68603	WO	A2	2001-09-20	Bristol-Myers Squibb Co.	<input type="checkbox"/>
10	03/000180	WO	A2	2003-01-03	Merck & Co, Inc.	<input type="checkbox"/>
11	03/004498	WO	A1	2003-01-16	Merck & Co, Inc.	<input type="checkbox"/>
12	03/082817	WO	A2	2003-10-09	Merck & Co, Inc.	<input type="checkbox"/>
13	04/043940	WO	A1	2004-05-27	Merck & Co, Inc.	<input type="checkbox"/>
14	04/037169	WO	A2	2004-05-06	Merck & Co, Inc.	<input type="checkbox"/>
15	02/076450	WO	A1	2002-10-03	Merck & Co, Inc	<input type="checkbox"/>
16	06/040625	WO	A1	2006-04-20	Glenmark Pharmaceutical's S.A.	<input type="checkbox"/>
17	05/095343	WO	A1	2005-10-13	Graffinity Pharmaceutical's AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
-----------------------	------------	---	----------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595386
Filing Date		2004-10-11
First Named Inventor	Roger Butlin	
Art Unit	1751	
Examiner Name	Not yet assigned	
Attorney Docket Number	101243-1P US	

1	YAMADA, M et al, "A Potent Dipeptide Inhibitor of Dipeptidyl Peptidase IV", Bioorganic & Medicinal Chemistry Letters, 1998, pages 1537-1540, Vol 8(12).	<input type="checkbox"/>
2	LENDECKEL, U et al, "Synergistic Action of DPIV and APN in the Regulation of T Cell Function", Advances in Exptl Medicine and Biology, 2003, pages 123-131, Vol 524.	<input type="checkbox"/>
3	IKEMOTO, N et al, "Highly Diastereoselective Heterogeneously Catalyzed Hydrogenation of Enamines for the Synthesis of Chiral beta-Amino Acid Derivatives", J. Am. Chem. Soc, 20, pages 3048-3049, Vol 126.	<input type="checkbox"/>
4	AUGUSTYNS, K et al, The Unique Properties of Dipeptidyl-peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV Inhibitors", Current Medicinal Chemistry, 1999, pages 311-327, Vol 6.	<input type="checkbox"/>
5	DEACON, C, "Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes", The International Journal of Biochemistry and Cell Biology", 2006, pages 831-844, Vol 38.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.